> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Liquidia CEO Says United Wanted All PH-ILD Revenue Through 2042 Plus Half Of PAH Revenue
- URL: https://www.bullished.co/liquidia-ceo-says-united-wanted-all-ph-ild-revenue-through-2042-plus-half-of-pah-revenue-9d9e20a4/
- Published: 2026-11-10T14:40:57.000Z
- Updated: 2026-11-14T00:30:38.000Z
- Description: Liquidia expects to fund its accepted settlement with existing cash and drug sales, without additional capital or operating changes.
- Author: Matteo Parrino
- Tags: Earnings, LQDA, Industry: Healthcare

[Liquidia](https://www.bullished.co/tag/lqda/), which develops and sells respiratory and vascular treatments, rejected a settlement offer demanding all YUTREPIA revenue from patients with pulmonary hypertension associated with interstitial lung disease through 2042, Chief Executive Officer Dr. Roger Jeffs said on Tuesday's earnings call. United Therapeutics also wanted 50% of non-infringing pulmonary arterial hypertension revenue, he said.

## Why Jeffs Rejected The Offer

Jeffs challenged United's description of an offer that would have kept YUTREPIA available for both diseases. Responding to an analyst's question, he said United had made only one proposal and called its characterization of the terms "grossly misleading".

Taking all revenue from the lung-disease indication, known as PH-ILD, would leave Liquidia paying to manufacture and distribute the treatment without retaining the proceeds, Jeffs said. The arrangement "would actually be a loss leader for us", he told analysts.

The companies ultimately reached a different agreement on October 13 that [resolved all litigation](https://www.sec.gov/Archives/edgar/data/0001819576/000110465926124770/tm2629427d1%5Fex99-1.htm?ref=bullished.co), covering six pending lawsuits, according to Liquidia's results release. That followed a September 30 ruling by the U.S. District Court for the District of Delaware that certain patent claims covering PH-ILD treatment with inhaled treprostinil were valid and infringed.

Liquidia agreed not to appeal, stopped promoting YUTREPIA for PH-ILD and submitted an application to remove that indication from the label. Existing patients are not required to stop treatment; promotion now centers on pulmonary arterial hypertension, or PAH.

## Fixed Payments, No Continuing Royalty

Chief Operating Officer and Chief Financial Officer Michael Kaseta said Liquidia needs no additional capital and plans no operating changes to meet the accepted settlement's $380.7 million in net cash obligations. Management expects to fund the payments with cash and ongoing YUTREPIA sales.

The final installment is due in April 2027\. Kaseta said United will receive no royalties or continuing payments afterward, leaving Liquidia and its shareholders with the benefit of subsequent PAH growth.

Liquidia ended September with [$396.1 million](https://www.globenewswire.com/news-release/2026/11/10/3399286/0/en/liquidia-corporation-reports-third-quarter-2026-financial-results.html?ref=bullished.co) in cash before settlement payments, compared with $190.7 million at the end of 2025\. Third-quarter net loss was $236.3 million, including a $389.7 million settlement charge; adjusted earnings before interest, taxes, depreciation and amortization reached $140.5 million.

YUTREPIA is a dry-powder inhaled form of treprostinil, approved in May 2025 and launched in June 2025\. Liquidia's separate profit-sharing promotion agreement with Sandoz for generic treprostinil injection ended in October, ending that service-revenue stream.

## Referrals Reset, Shipments Reach A High

Third-quarter YUTREPIA sales reached [$222.7 million](https://www.globenewswire.com/news-release/2026/11/10/3399286/0/en/liquidia-corporation-reports-third-quarter-2026-financial-results.html?ref=bullished.co), up 31% from the second quarter. Paid patient demand accounted for $212.2 million; Kaseta attributed the difference to inventory stocking as demand expanded.

Jeffs said prescriptions, revenue and adjusted earnings had grown for five consecutive quarters. More than 70% of September referrals included a PAH diagnosis, compared with more than 60% from launch through September.

October patient shipments reached their highest monthly level since launch, even as daily referrals exceeded only 75% of the third-quarter rate. Jeffs described October as a floor rather than a continuing decline and said uncertainty surrounding the litigation had paused referrals at some centers.

Conversion of referrals into patient starts remained above 87%, and the prescriber base reached 1,300 through October. Kaseta said payer contracts and formulary placement had not changed and that management expects no change to reauthorizations.

Asked by a Needham analyst about disruption, Jeffs defended YUTREPIA's clinical profile: "So you can't litigate that away."

Kaseta said management expects to provide its 2027 outlook in early January, after gathering more post-settlement operating data.

Learn

- [How To Read An Earnings Call Transcript: Start With Guidance, Then Find What's Missing →](https://www.bullished.co/learn/how-to-read-an-earnings-call/)  
How to read an earnings call transcript: check guidance first, look for dropped metrics, compare growth with last quarter, and watch hedged wording.

### Sources

- [Liquidia results release (Form 8-K, EX-99.1)](https://www.sec.gov/Archives/edgar/data/0001819576/000110465926124770/tm2629427d1%5Fex99-1.htm?ref=bullished.co) — SEC EDGAR
- [Liquidia Corporation (LQDA) Q3 Earnings and Revenues Beat Estimates](https://finance.yahoo.com/markets/stocks/articles/liquidia-corporation-lqda-q3-earnings-114001622.html?ref=bullished.co) — Yahoo Finance
- [Liquidia GAAP EPS of -$2.64 misses by $3.60, revenue of $225.3M beats by $11.15M (LQDA:NASDAQ) | Seeking Alpha](https://seekingalpha.com/news/4669636-liquidia-gaap-eps-of-2%5F64-misses-by-3%5F60-revenue-of-225%5F3m-beats-by-11%5F15m?ref=bullished.co) — seekingalpha.com
- [Liquidia (LQDA) Stock Looks Rich Relative To Its Earnings Power](https://finance.yahoo.com/markets/stocks/articles/liquidia-lqda-stock-looks-rich-031154693.html?ref=bullished.co) — Yahoo Finance
- [Life Sciences : Law360 : Legal News & Analysis](https://www.law360.com/lifesciences/news?%3Bpage=479&page=7&ref=bullished.co) — law360.com
- [Liquidia Corporation Reports Third Quarter 2026 Financial](https://www.globenewswire.com/news-release/2026/11/10/3399286/0/en/liquidia-corporation-reports-third-quarter-2026-financial-results.html?ref=bullished.co) — globenewswire.com

### More on Liquidia

- [Liquidia's YUTREPIA Sales Climb 31% — But A Settlement Charge Pushes It Into Loss](https://www.bullished.co/liquidias-yutrepia-sales-climb-31-but-a-settlement-charge-pushes-it-into-loss-80b6744e/)
- [Liquidia Settles All Six United Therapeutics Suits, Will Pay Net $380.7 Million Through 2027](https://www.bullished.co/liquidia-settles-all-six-united-therapeutics-suits-will-pay-net-380-7-million-through-2027-9bfe8196/)

[All Liquidia (LQDA) coverage →](https://www.bullished.co/tag/lqda/)